samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Stevanato Group

SG US TEC will add biocompatibility, microbiology, extractable & leachable testing, and toxicological evaluation to its analytical technique suite to investigate drug-container closure system interaction.

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.

The collaboration combines the best-in-class knowledge, expertise, and capabilities of both companies. The SG US TEC, opening in Boston on September 24th, will provide analytical services on material properties, physical and mechanical performances to investigate the potential interactions between drugs and glass-based primary packaging. Thanks to this collaborative agreement, Nelson Labs will support the SG US TEC with toxicological evaluation, biocompatibility, microbiology, and extractables and leachables testing.

Over the years, Nelson Labs has built a set of advanced analytical methodologies, using cutting-edge technologies and state-of-the-art instrumentation. Besides, Nelson Labs boasts a wide range of exclusive analytical and toxicological databases, allowing its staff to optimize their methodologies and data interpretation further.

“With our laboratory in Italy, SG Lab, we have collaborated for many years with Nelson Labs’ European Center of Excellence, Nelson Labs. We are glad to extend this collaboration also to our US customers. Its recognized expertise in extractables and leachables testing applied to biologics is crucial to ensure that the packaging system does not adulterate the drug product, ensuring drug efficacy, and patient safety. Combining SG US TEC skilled scientists with Nelson Labs’ experts and cutting-edge laboratory capabilities, we can now offer comprehensive analytical services assessing drug compatibility with container closure systems and devices/combination products.” says Abizer Harianawala, Site Leader at US TEC.

“When it comes to the E&L qualification process of the primary packaging, biologics face additional challenges compared to small-molecule drugs. The efficacy of the therapeutic biologic could be compromised through undesirable interaction of leachables with the drug substance, resulting in side-effects and product recalls. Nelson Labs’ in-depth scientific knowledge of extractables and leachables testing - including toxicological assessments - will allow biopharmaceutical companies to move much faster in the qualification and acceptance process of their selected container closure system.” says Piet Christiaens, Scientific Director at Nelson Labs Europe.

About Stevanato Group: Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historic brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment.

The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group is able to offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, please visit www.stevanatogroup.com

About Nelson Labs:
Nelson Labs, a Sotera Health company, is a leading, global provider of lab testing and expert advisory services. We perform microbiological and analytical laboratory tests across the medical device, pharmaceutical, and tissue industries. The company is regarded as a best-in-class provider with a strong track record of collaborating with customers to solve complex problems. We have over 500 scientists, technicians, and service specialists who diligently perform more than 800 rigorous tests in 13 global laboratory locations.

Based in Belgium, Nelson Labs Europe specializes in providing premium extractables & leachables testing services to the pharmaceutical and medical device industries. We also support pharmaceutical companies across the globe in developing worldwide compliance testing strategies to qualify container/closure applications and pharmaceutical production equipment from an extractables & leachables perspective. With decades of expertise, we stand behind the quality of our results and the strength or our customer partnerships. Along with our sister companies Sterigenics and Nordion, we are part of Sotera Health, the leading protector of global health.

For more information, please visit www.nelsonlabs.com
phone +39 049 9318111
web www.stevanatogroup.com
email Via Molinella, 17 - 35017 Piombino Dese - Padua
 
Print this page
Send to a friend
   
spacer
News and Press Releases

SHIONOGI’S NOVEL ANTIBIOTIC, FETCROJA® (CEFIDEROCOL), HAS BEEN SELECTED BY UK’S NICE / NHSE&I AS PART OF AN ANTIMICROBIAL SUBSCRIPTION STYLE REIMBURSEMENT MODEL

The National Institute for Clinical and Health Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) have recognised the potential of Shionogi’s innovative antibiotic, cefiderocol, and selected it for inclusion in this pilot reimbursement model which ‘de-links’ payment from volume of use Shionogi recognises the UK’s leadership role in introducing this first fully ‘delinked’ pilot reimbursement model, which is an important step in making the market for novel antibiotics more predictable and sustainable; we strongly believe in the introduction of further suitable pull incentives in order to help stimulate the antimicrobial development pipeline Fetcroja® (cefiderocol) is indicated for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options1 Antimicrobial resistance (AMR) is a major health burden which results in over 700,000 deaths globally2 and 5,000 deaths per year in the UK3 from an infection with multidrug-resistant bacteria and this is predicted to kill 10 million people every year globally by 2050, unless action is taken2
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement